Leading Experts Disagree on Evidence behind Prostate Cancer Screening Recommendations

 

Is Randomized Trial Data Enough to Recommend Against Routine PSA Screening? \’Point/Counterpoint\’ Debate in Medical Care

Newswise — Philadelphia, Pa. (March 25, 2013) – Do the results of recent randomized trials justify the recent U.S. recommendation against yearly measurement of prostate-specific antigen (PSA) as a screening test for prostate cancer? That\’s the topic of debate in a special \”point/counterpoint\” section in the April issue of Medical Care. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

This post was imported from a legacy archive. Please excuse any formatting inconsistencies.

Leave a Reply

Your email address will not be published. Required fields are marked *